Proteomics International Laboratories Ltd (PIQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Proteomics International Laboratories Ltd (PIQ) has a cash flow conversion efficiency ratio of -0.132x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-950.22K ≈ $-672.34K USD) by net assets (AU$7.21 Million ≈ $5.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PIQ company net worth for the company's overall valuation and market capitalisation.
Proteomics International Laboratories Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Proteomics International Laboratories Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Proteomics International Laboratories Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Proteomics International Laboratories Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Proteomics International Laboratories Lt to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Minnova Corp
V:MCI
|
0.162x |
|
Panostaja Oyj
HE:PNA1V
|
0.238x |
|
Lighting and Equipment Public Company Limited
BK:L&E
|
0.013x |
|
IRLAB Therapeutics AB (publ)
ST:IRLAB-A
|
-0.787x |
|
Trinity Watthana Public Company Limited
BK:TNITY
|
0.056x |
|
NYESA VALOS CO.EO 001
F:7NY0
|
N/A |
|
Hank Payments Corp
V:HANK
|
0.083x |
|
Travis Perkins PLC
LSE:TPK
|
0.086x |
Annual Cash Flow Conversion Efficiency for Proteomics International Laboratories Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Proteomics International Laboratories Ltd from 2014 to 2025. View Proteomics International Laboratories Lt stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$12.97 Million ≈ $9.18 Million |
AU$-6.60 Million ≈ $-4.67 Million |
-0.509x | +15.78% |
| 2024-06-30 | AU$9.25 Million ≈ $6.54 Million |
AU$-5.59 Million ≈ $-3.96 Million |
-0.605x | +11.59% |
| 2023-06-30 | AU$8.32 Million ≈ $5.89 Million |
AU$-5.69 Million ≈ $-4.03 Million |
-0.684x | +34.43% |
| 2022-06-30 | AU$3.39 Million ≈ $2.40 Million |
AU$-3.54 Million ≈ $-2.50 Million |
-1.043x | -259.29% |
| 2021-06-30 | AU$7.61 Million ≈ $5.38 Million |
AU$-2.21 Million ≈ $-1.56 Million |
-0.290x | -235.07% |
| 2020-06-30 | AU$4.44 Million ≈ $3.14 Million |
AU$-384.51K ≈ $-272.06K |
-0.087x | +84.48% |
| 2019-06-30 | AU$2.99 Million ≈ $2.11 Million |
AU$-1.67 Million ≈ $-1.18 Million |
-0.558x | -140.84% |
| 2018-06-30 | AU$4.68 Million ≈ $3.31 Million |
AU$-1.08 Million ≈ $-766.91K |
-0.232x | +74.63% |
| 2017-06-30 | AU$1.61 Million ≈ $1.14 Million |
AU$-1.47 Million ≈ $-1.04 Million |
-0.914x | +52.09% |
| 2016-06-30 | AU$791.42K ≈ $559.98K |
AU$-1.51 Million ≈ $-1.07 Million |
-1.907x | -408.33% |
| 2015-06-30 | AU$1.81 Million ≈ $1.28 Million |
AU$-677.26K ≈ $-479.21K |
-0.375x | -469.06% |
| 2014-06-30 | AU$4.94 Million ≈ $3.50 Million |
AU$-325.72K ≈ $-230.47K |
-0.066x | -- |
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more